← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 3
Taxane Compound (Taxane Compound)
SWOG Cancer Research Network·HER2
ORR 69.3%
Overview
Program
Taxane Compound
Overview
Company
SWOG Cancer Research Network
Overview
Modality
ADC
Overview
Target
HER2
Overview
Indication
Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
MoA
Mechanism
targeting this shared pathway
MoA
Biomarker
biomarker in Triple negative breast cancer
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Human, Mouse, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Human, Mouse, In vitro
Toxicology
Major finding
Isolation, Purification, and Preparation of Taxinine-Loaded Liposomes for Improved Anti-Hepatocarcinogenic Activity.. Liver cancer is the fourth most deadly cancer worldwide, but existing treatment options are insufficient, thus highlighting the urgent need for new therapeutic agents. Taxanes, known for their anticancer properties, provide a promising avenue for intervention. In this study, a tetr…
Clinical
Primary efficacy
ORR 69.3%
Clinical
ORR
69.3%
Clinical
Result source
ClinicalTrials.gov NCT01120184
Clinical
Data Tier / Score
A · 65
Clinical
Program phase
PHASE_3
Clinical
Clinical sync
2026년 7월 18일 (8일 전)